Reaction
Exposure To Sars-Cov-2 reporting signals
As of the last recalculation, Exposure To Sars-Cov-2 appears in 1,696 FAERS reports alongside 33 co-occurring drug terms. The strongest observed disproportionality signal is INFLIXIMAB-DYYB (PRR 67.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Infliximab-Dyyb | 146 | 67.0 | 67.3 |
| Ampicillin | 24 | 36.1 | 36.2 |
| Ampicillin Sodium | 24 | 36.1 | 36.2 |
| Minocycline | 20 | 21.3 | 21.3 |
| Cladribine | 15 | 19.3 | 19.3 |
| Diphenhydramine Hydrochloride Capsule, Liquid Filled | 33 | 19.3 | 19.3 |
| Erythromycin | 29 | 19.3 | 19.3 |
| Agalsidase Beta | 13 | 17.4 | 17.4 |
| Infliximab | 221 | 14.1 | 14.1 |
| Pantoprazole Sodium In 0.9% Sodium Chloride | 61 | 12.5 | 12.5 |
| Pantoprazole Sodium Injection | 61 | 12.5 | 12.5 |
| Carboxymethylcellulose Sodium | 9 | 11.8 | 11.8 |
| Hydrocortisone Sodium Succinate | 9 | 11.8 | 11.8 |
| Fluticasone Furoate | 11 | 11.2 | 11.2 |
| Mesalamine | 47 | 10.5 | 10.5 |
| Diphenhydramine | 50 | 10.0 | 10.0 |
| Certolizumab Pegol | 88 | 9.7 | 9.7 |
| Mepolizumab | 33 | 8.3 | 8.3 |
| Cetirizine Hydrochloride Allergy | 18 | 7.4 | 7.4 |
| Cetirizine Hydrochloride Tablets | 18 | 7.4 | 7.4 |
| Dexamethasone Sodium Phosphate | 6 | 7.3 | 7.3 |
| Ofatumumab | 18 | 6.7 | 6.7 |
| Lanreotide Acetate | 4 | 6.3 | 6.3 |
| Omalizumab | 39 | 5.7 | 5.7 |
| Siponimod | 4 | 5.5 | 5.5 |
| Tofacitinib | 67 | 4.6 | 4.6 |
| Benralizumab | 6 | 3.7 | 3.7 |
| Glecaprevir And Pibrentasvir | 3 | 3.4 | 3.4 |
| Nirmatrelvir And Ritonavir | 12 | 2.7 | 2.7 |
| Romosozumab-Aqqg | 3 | 2.7 | 2.7 |
| Dupilumab | 79 | 2.1 | 2.1 |
| Voxelotor | 3 | 1.6 | 1.6 |
| Apremilast | 19 | 1.6 | 1.6 |